Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Cullinan Therapeutics, Inc. (CGEM) had Free Cash Flow per Share of $-1.37 for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-53.70M |
|
-- |
|
-- |
|
$57.25M |
|
$-57.25M |
|
$3.55M |
|
$-53.70M |
|
$-53.70M |
|
$-53.70M |
|
$-53.70M |
|
$-53.70M |
|
$-53.70M |
|
$-57.25M |
|
$-57.17M |
|
61.49M |
|
61.49M |
|
$-0.81 |
|
$-0.81 |
|
| Balance Sheet Financials | |
$341.97M |
|
$0.26M |
|
$21.81M |
|
$363.79M |
|
$40.63M |
|
-- |
|
$1.41M |
|
$42.03M |
|
$321.75M |
|
$321.75M |
|
$321.75M |
|
64.35M |
|
| Cash Flow Statement Financials | |
$-84.26M |
|
$73.09M |
|
$1.48M |
|
$88.33M |
|
$78.64M |
|
$-9.69M |
|
$16.06M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.42 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-84.26M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-16.69% |
|
-16.69% |
|
-14.76% |
|
-16.69% |
|
$5.00 |
|
|
Free Cash Flow per Share |
$-1.37 |
$-1.37 |
|